Anti-FAP monoclonal antibody F19-I-131

Drug Profile

Anti-FAP monoclonal antibody F19-I-131

Alternative Names: Anti-fibroblast activation protein monoclonal antibody F19; F19 monoclonal antibody I-131

Latest Information Update: 15 Aug 2007

Price : $50

At a glance

  • Originator Boehringer Ingelheim; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center
  • Class Monoclonal antibodies
  • Mechanism of Action Fibroblast activation protein antagonists; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 16 Oct 2003 No development reported - Phase-I for Solid tumours in Australia (Infusion)
  • 16 Oct 2003 No development reported - Phase-I for Solid tumours in Germany (Infusion)
  • 16 Oct 2003 No development reported - Phase-I for Solid tumours in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top